[go: up one dir, main page]

AR131560A1 - Methods for treating POTS using FCRN antagonists - Google Patents

Methods for treating POTS using FCRN antagonists

Info

Publication number
AR131560A1
AR131560A1 ARP240100028A ARP240100028A AR131560A1 AR 131560 A1 AR131560 A1 AR 131560A1 AR P240100028 A ARP240100028 A AR P240100028A AR P240100028 A ARP240100028 A AR P240100028A AR 131560 A1 AR131560 A1 AR 131560A1
Authority
AR
Argentina
Prior art keywords
pots
treating
fcrn
methods
treatment
Prior art date
Application number
ARP240100028A
Other languages
Spanish (es)
Inventor
Middendorp Joost Van
Tae Hwan Chung
Original Assignee
argenx BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV filed Critical argenx BV
Publication of AR131560A1 publication Critical patent/AR131560A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente descripción se proporcionan métodos para tratar el síndrome de taquicardia ortostática postural (POTS) mediante el uso de una cantidad eficaz de un antagonista del receptor de Fc neonatal (FcRn) humano. En la presente descripción también se proporcionan antagonistas de FcRn para su uso en el tratamiento de POTS y para su uso en la fabricación de un medicamento para el tratamiento de POTS. Reivindicación 1: Un método para tratar el síndrome de taquicardia ortostática postural (POTS) en un sujeto que lo necesita, el método comprende administrar al sujeto una cantidad eficaz de un antagonista del receptor de Fc neonatal (FcRn) humano. Reivindicación 55: Un antagonista de FcRn para su uso en el tratamiento de POTS, en donde el tratamiento se realiza de acuerdo con el método de cualquiera de las reivindicaciones 1 - 54. Reivindicación 56: Un antagonista de FcRn para su uso en la fabricación de un medicamento para el tratamiento de POTS, en donde el tratamiento se realiza de acuerdo con el método de cualquiera de las reivindicaciones 1 - 54.Provided herein are methods of treating postural orthostatic tachycardia syndrome (POTS) using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. Also provided herein are FcRn antagonists for use in treating POTS and for use in the manufacture of a medicament for treating POTS. Claim 1: A method of treating postural orthostatic tachycardia syndrome (POTS) in a subject in need thereof, the method comprising administering to the subject an effective amount of a human neonatal Fc receptor (FcRn) antagonist. Claim 55: An FcRn antagonist for use in the treatment of POTS, wherein the treatment is carried out according to the method of any one of claims 1 - 54. Claim 56: An FcRn antagonist for use in the manufacture of a medicament for the treatment of POTS, wherein the treatment is carried out according to the method of any one of claims 1 - 54.

ARP240100028A 2023-01-06 2024-01-05 Methods for treating POTS using FCRN antagonists AR131560A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363437552P 2023-01-06 2023-01-06

Publications (1)

Publication Number Publication Date
AR131560A1 true AR131560A1 (en) 2025-04-09

Family

ID=89983623

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100028A AR131560A1 (en) 2023-01-06 2024-01-05 Methods for treating POTS using FCRN antagonists

Country Status (3)

Country Link
AR (1) AR131560A1 (en)
TW (1) TW202432178A (en)
WO (1) WO2024147074A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005981A (en) 2017-12-08 2020-08-24 Argenx Bvba USE OF CRFN ANTAGONISTS FOR THE TREATMENT OF GENERALIZED MYASTENIA GRAVIS.
CN112513073A (en) 2018-06-08 2021-03-16 阿根思公司 Compositions and methods for treating immune thrombocytopenia
US12403175B2 (en) 2020-01-08 2025-09-02 argenx BV Methods for treating pemphigus disorders
WO2023242372A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn/hsa binding molecules and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2687117A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
KR102505995B1 (en) * 2016-07-29 2023-03-08 모멘타 파머슈티컬스 인코포레이티드 FcRn Antibodies and Methods of Using The Same
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
MX2020005981A (en) 2017-12-08 2020-08-24 Argenx Bvba USE OF CRFN ANTAGONISTS FOR THE TREATMENT OF GENERALIZED MYASTENIA GRAVIS.
WO2021022249A1 (en) * 2019-08-01 2021-02-04 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Also Published As

Publication number Publication date
WO2024147074A1 (en) 2024-07-11
TW202432178A (en) 2024-08-16

Similar Documents

Publication Publication Date Title
AR131560A1 (en) Methods for treating POTS using FCRN antagonists
AR131601A1 (en) Methods for treating primary Sjogren's syndrome using FcRn antagonists
MX2018016330A (en) COMBINATIONS FOR CANCER TREATMENT.
MX2024010165A (en) METHODS FOR TREATING MYOSITIS USING FCRN ANTAGONISTS.
AR130995A1 (en) Methods for the treatment of primary membrane-bound nephropathies using FCN antagonists
MX2021014161A (en) Methods of treating sjã–gren's syndrome using a bruton's tyrosine kinase inhibitor.
MX2023003942A (en) METHODS FOR THE TREATMENT OF ASTHMA IN PEDIATRIC SUBJECTS THROUGH THE ADMINISTRATION OF AN IL-4R ANTAGONIST.
MX2024013015A (en) Methods for treating bullous pemphigoid using fcrn antagonists
CL2021003032A1 (en) Methods of treating chronic spontaneous urticaria using a Bruton's tyrosine kinase inhibitor.
ECSP22089498A (en) IL4I1 INHIBITORS AND METHODS OF USE
Webster et al. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain
MX2025005378A (en) Methods for the treatment of cardiovascular disease
CL2024002627A1 (en) Polymorphic forms of aticaprant for use in the treatment of major depressive disorder.
MX2022016406A (en) METHODS FOR TREATING CANCER OR VON-HIPPEL LINDAU DISEASE USING A COMBINATION OF A HIF-2 ALPHA INHIBITOR AND LENVATINIB.
MX2022016410A (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof.
Albagieh et al. Efficacy of lidocaine versus mepivacaine in the management of myofascial pain
Velázquez-Delgado et al. Postoperative analgesia with dexmedetomidine in interscalene block. Comparative study
Singh Autologous blood versus corticosteroid local injection for treatment of lateral epicondylosis: a randomized clinical trial
CL2022000496A1 (en) Methods for the treatment of cln2 disease in pediatric subjects
Aufiero et al. Treatment of medial and lateral elbow tendinosis with an injectable amniotic membrane allograft: a retrospective case series
EA202000298A1 (en) ANTICORONAVIRUS AGENT FOR COMBINATION THERAPY OF COVID-19 (SARS-CoV-2) AND METHOD OF TREATMENT
AR128568A1 (en) METHODS TO TREAT MYOSITIS THROUGH THE USE OF FCRN ANTAGONISTS
Kayatha et al. Treatment outcome of tennis elbow by percutaneous needle tenotomy
de Almeida Paz et al. Effects of ischemic compression of trigger points in painful episodes of patients with chronic shoulder pain. Systematic Review.
CHOWDARY EVALUATION OF USEFULNESS OF LASER THERAPY IN MANAGEMENT OF DIABETIC FOOT ULCER

Legal Events

Date Code Title Description
FB Suspension of granting procedure